Via360 Expands Canal-Based MIGS Options
Clinical Scorecard: Via360 Expands Canal-Based MIGS Options
At a Glance
Category Detail
Condition Open-Angle Glaucoma Key Mechanisms Combination of canaloplasty and trabeculotomy with controlled viscodilation. Target Population Patients with elevated intraocular pressure (IOP) and medication dependency. Care Setting Ophthalmic surgical settings.
Key Highlights
510(k) clearance from the FDA for controlled viscoelastic delivery. Surgeon-controlled, on-demand viscoelastic delivery via ActiveInject technology. Microcatheter design allows advancement up to 360° within Schlemm’s canal. Effective for patients with pigment dispersion syndrome, pseudoexfoliation syndrome, and steroid response glaucoma. Reduces the need for filtering surgery in cases of significant IOP elevation. Guideline-Based Recommendations
Diagnosis
Consider MIGS for patients who may benefit from IOP reduction and reduced medication burden. Management
Utilize Via360 for maximum IOP lowering through combined canaloplasty and trabeculotomy. Monitoring & Follow-up
Monitor IOP and medication dependency post-procedure. Risks
Potential for catheter entering unintended areas, though tactile feedback aids in navigation. Patient & Prescribing Data
Patients with open-angle glaucoma and elevated outflow resistance.
Significant reductions in IOP and topical medication burden observed.
Clinical Best Practices
Employ ActiveInject technology for precise viscoelastic delivery. Utilize the rotatable cannula for access in complex anatomical cases. Streamline surgical prep with the Smart Prime feature to optimize viscoelastic volume. Related Resources & Content
